Ifmad

Last updated
International Forum on Mood and Anxiety Disorders
AbbreviationIFMAD
Formation2000
Headquarters Monaco (Principality of Monaco)
Chairman
 Siegfried Kasper
Co-Chairman
Stuart Montgomery
Website ifmad.org

International Forum on Mood and Anxiety Disorders or IFMAD is a professional organisation with the aim of spreading awareness of the latest international trend, research and innovations related to mood and anxiety disorders while encouraging the exchange of ideas among the psychiatric community all over the world. [1] [2] Professor Siegfried Kasper and Professor Stuart Montgomery jointly founded IFMAD in the year 2000 which received supports from a scientific committee composed of prominent individuals in the domain of mood and anxiety disorders from across the world. [3]

Contents

Activities

The organization is known to convey annual congress to encourage discussion and debate in the field of mood and anxiety disorder. This annual event has become an important forum for the exchange of ideas and a key part of the congress calendar. [4] IFMAD is affiliated with the Union of International Associations. [1] The 18th International Forum on Mood and Anxiety Disorders held in Vienna received endorsement from various organizations including the Association Internationale pour la promotion de Formations Spécialisées en Médecine et en Sciences Biologiques (AFISM). [5]

Conferences

YearTitleVenueAbstractFinal ProgramWebsiteReferences
2025"20th International Forum on Mood and Anxiety Disorders (IFMAD) (04 - 06 June 2025)" Budapest [6] [7] [8]
2021"19th International Forum on Mood and Anxiety Disorders (22 -24 July 2021)"Virtual edition [9] [10] [11]
2019"18th International Forum on Mood and Anxiety Disorders (4 - 6 July 2019)" Vienna [12] [13] [14] [15] [16]
2017"17th International Forum on Mood and Anxiety Disorders (14 - 17 December 2017)" Madrid [17] [18] [19] [20] [21]
2016"16th International Forum on Mood and Anxiety Disorders (8 - 10 December 2016)" Rome [22] [23] [24] [25]
2015"15th International Forum on Mood and Anxiety Disorders (2 - 4 December 2015)" Prague [26] [27] [28] [29]
2014"14th International Forum on Mood and Anxiety Disorders (from 10 to 12 December 2014)" Vienna [30] [31] [32] [33]
2013"13th International Forum on Mood and Anxiety Disorders" Monaco [34] [35] [36] [37]
2012"12th International Forum on Mood and Anxiety Disorders" Barcelona [38] [39] [40] [41]
2011"11th International Forum on Mood and Anxiety Disorders" Budapest [42] [43] [44] [45]
2010"10th International Forum on Mood and Anxiety Disorders" Vienna [46] [47] [48]
2009"9th International Forum on Mood and Anxiety Disorders" Monaco [49] [50] [51]
2008"8th International Forum on Mood and Anxiety Disorders" Vienna [52] [53] [54]
2007"7th International Forum on Mood and Anxiety Disorders" Budapest [55] [56] [57]
2006"6th International Forum on Mood and Anxiety Disorders" Vienna [58] [59] [60]
2005"5th International Forum on Mood and Anxiety Disorders" Vienna [61] [62] [63]
2003"4th International Forum on Mood and Anxiety Disorders" Monaco [64] [65] [66] [67]
2002"3rd International Forum on Mood and Anxiety Disorders" Monaco [68] [69]
2001"2nd International Forum on Mood and Anxiety Disorders" Monaco [70] [71]
2000"1st International Forum on Mood and Anxiety Disorders" Monaco [72] [73]

Related Research Articles

<span class="mw-page-title-main">Anxiety</span> Unpleasant state of inner turmoil over anticipated events

Anxiety is an emotion characterised by an unpleasant state of inner turmoil and includes feelings of dread over anticipated events. Anxiety is different from fear in that fear is defined as the emotional response to a present threat, whereas anxiety is the anticipation of a future one. It is often accompanied by nervous behavior such as pacing back and forth, somatic complaints, and rumination.

<span class="mw-page-title-main">Benzodiazepine</span> Class of depressant drugs

Benzodiazepines, colloquially known as "benzos", are a class of depressant drugs whose core chemical structure is the fusion of a benzene ring and a diazepine ring. They are prescribed to treat conditions such as anxiety disorders, insomnia, and seizures. The first benzodiazepine, chlordiazepoxide (Librium), was discovered accidentally by Leo Sternbach in 1955, and was made available in 1960 by Hoffmann–La Roche, which followed with the development of diazepam (Valium) three years later, in 1963. By 1977, benzodiazepines were the most prescribed medications globally; the introduction of selective serotonin reuptake inhibitors (SSRIs), among other factors, decreased rates of prescription, but they remain frequently used worldwide.

<span class="mw-page-title-main">Major depressive disorder</span> Mood disorder

Major depressive disorder (MDD), also known as clinical depression, is a mental disorder characterized by at least two weeks of pervasive low mood, low self-esteem, and loss of interest or pleasure in normally enjoyable activities. Introduced by a group of US clinicians in the mid-1970s, the term was adopted by the American Psychiatric Association for this symptom cluster under mood disorders in the 1980 version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III), and has become widely used since. The disorder causes the second-most years lived with disability, after lower back pain.

<span class="mw-page-title-main">Mood disorder</span> Mental disorder affecting the mood of an individual, over a long period of time

A mood disorder, also known as an affective disorder, is any of a group of conditions of mental and behavioral disorder where the main underlying characteristic is a disturbance in the person's mood. The classification is in the Diagnostic and Statistical Manual of Mental Disorders (DSM) and International Classification of Diseases (ICD).

A psychiatric or psychotropic medication is a psychoactive drug taken to exert an effect on the chemical makeup of the brain and nervous system. Thus, these medications are used to treat mental illnesses. These medications are typically made of synthetic chemical compounds and are usually prescribed in psychiatric settings, potentially involuntarily during commitment. Since the mid-20th century, such medications have been leading treatments for a broad range of mental disorders and have decreased the need for long-term hospitalization, thereby lowering the cost of mental health care. The recidivism or rehospitalization of the mentally ill is at a high rate in many countries, and the reasons for the relapses are under research.

<span class="mw-page-title-main">Sertraline</span> Antidepressant (SSRI class) medication

Sertraline, sold under the brand name Zoloft among others, is an antidepressant medication of the selective serotonin reuptake inhibitor (SSRI) class used to treat major depressive disorder, generalized anxiety disorder, social anxiety disorder, obsessive–compulsive disorder (OCD), panic disorder, and premenstrual dysphoric disorder. Although also having approval for post-traumatic stress disorder (PTSD), findings indicate it leads to only modest improvements in symptoms associated with this condition.

<span class="mw-page-title-main">Alprazolam</span> Benzodiazepine medication

Alprazolam, sold under the brand name Xanax among others, is a fast-acting, potent tranquilizer of moderate duration within the triazolobenzodiazepine group of chemicals called benzodiazepines. Alprazolam is most commonly prescribed in the management of anxiety disorders, especially panic disorder and generalized anxiety disorder (GAD). Other uses include the treatment of chemotherapy-induced nausea, together with other treatments. GAD improvement occurs generally within a week. Alprazolam is generally taken orally.

<span class="mw-page-title-main">Depression (mood)</span> State of low mood and aversion to activity

Depression is a mental state of low mood and aversion to activity. It affects about 3.5% of the global population, or about 280 million people worldwide, as of 2020. Depression affects a person's thoughts, behavior, feelings, and sense of well-being. The pleasure or joy that a person gets from certain experiences is reduced, and the afflicted person often experiences a loss of motivation or interest in those activities. People with depression may experience sadness, feelings of dejection or hopelessness, difficulty in thinking and concentration, or a significant change in appetite or time spent sleeping; suicidal thoughts can also be experienced.

Adjustment disorder is a mental and behavioral disorder defined by a maladaptive response to a psychosocial stressor. The maladaptive response usually involves otherwise normal emotional and behavioral reactions that manifest more intensely than usual, causing marked distress, preoccupation with the stressor and its consequences, and functional impairment.

Atypical depression is defined in the DSM-IV as depression that shares many of the typical symptoms of major depressive disorder or dysthymia, but is characterized by improved mood in response to positive events. In contrast to those with atypical depression, people with melancholic depression generally do not experience an improved mood in response to normally pleasurable events. Atypical depression also often features significant weight gain or an increased appetite, hypersomnia, a heavy sensation in the limbs, and interpersonal rejection sensitivity that results in significant social or occupational impairment.

<span class="mw-page-title-main">Psychotic depression</span> Medical condition

Psychotic depression, also known as depressive psychosis, is a major depressive episode that is accompanied by psychotic symptoms. It can occur in the context of bipolar disorder or major depressive disorder. Psychotic depression can be difficult to distinguish from schizoaffective disorder, a diagnosis that requires the presence of psychotic symptoms for at least two weeks without any mood symptoms present. Unipolar psychotic depression requires that psychotic symptoms occur during severe depressive episodes, although residual psychotic symptoms may also be present in between episodes. Diagnosis using the DSM-5 involves meeting the criteria for a major depressive episode, along with the criteria for "mood-congruent or mood-incongruent psychotic features" specifier.

The Hamilton Rating Scale for Depression (HRSD), also called the Hamilton Depression Rating Scale (HDRS), sometimes also abbreviated as HAM-D, is a multiple-item questionnaire used to provide an indication of depression, and as a guide to evaluate recovery. Max Hamilton originally published the scale in 1960 and revised it in 1966, 1967, 1969, and 1980. The questionnaire is designed for adults and is used to rate the severity of their depression by probing mood, feelings of guilt, suicide ideation, insomnia, agitation or retardation, anxiety, weight loss, and somatic symptoms.

<span class="mw-page-title-main">Bipolar disorder in children</span>

Bipolar disorder in children, or pediatric bipolar disorder (PBD), is a rare mental disorder in children and adolescents. The diagnosis of bipolar disorder in children has been heavily debated for many reasons including the potential harmful effects of adult bipolar medication use for children. PBD is similar to bipolar disorder (BD) in adults, and has been proposed as an explanation for periods of extreme shifts in mood called mood episodes. These shifts alternate between periods of depressed or irritable moods and periods of abnormally elevated moods called manic or hypomanic episodes. Mixed mood episodes can occur when a child or adolescent with PBD experiences depressive and manic symptoms simultaneously. Mood episodes of children and adolescents with PBD are different from general shifts in mood experienced by children and adolescents because mood episodes last for long periods of time and cause severe disruptions to an individual's life. There are three known forms of PBD: Bipolar I, Bipolar II, and Bipolar Not Otherwise Specified (NOS). The average age of onset of PBD remains unclear, but reported age of onset ranges from 5 years of age to 19 years of age. PBD is typically more severe and has a poorer prognosis than bipolar disorder with onset in late-adolescence or adulthood.

The number of new psychiatric drugs, and especially antidepressants on the market in Japan, is significantly less than Western countries.

Compulsive buying disorder (CBD) is characterized by an obsession with shopping and buying behavior that causes adverse consequences. It "is experienced as a recurring, compelling and irresistible–uncontrollable urge, in acquiring goods that lack practical utility and very low cost resulting in excessive, expensive and time-consuming retail activity [that is] typically prompted by negative affectivity" and results in "gross social, personal and/or financial difficulties". Most people with CBD meet the criteria for a personality disorder. Compulsive buying can also be found among people with Parkinson's disease or frontotemporal dementia.

<span class="mw-page-title-main">Dennis S. Charney</span> American medical researcher

Dennis S. Charney is an American biological psychiatrist and researcher, with expertise in the neurobiology and treatment of mood and anxiety disorders. He is the author of Neurobiology of Mental Illness, The Physician's Guide to Depression and Bipolar Disorders and Molecular Biology for the Clinician, as well as the author of over 600 original papers and chapters. In 2022, he was listed #49 on Research.com's "Top Medicine Scientists in the United States," with an h-index of 218 with 173,960 citations across 887 publications. Charney is known for demonstrating that ketamine is effective for treating depression. Ketamine's use as a rapidly-acting anti-depressant is recognized as a breakthrough treatment in mental illness.

Mixed anxiety–depressive disorder (MADD) is a diagnostic category that defines patients who have both anxiety and depressive symptoms of limited and equal intensity accompanied by at least some autonomic nervous system features. Autonomic features are involuntary physical symptoms usually caused by an overactive nervous system, such as panic attacks or intestinal distress. The World Health Organization's ICD-10 describes Mixed anxiety and depressive disorder: "...when symptoms of anxiety and depression are both present, but neither is clearly predominant, and neither type of symptom is present to the extent that justifies a diagnosis if considered separately. When both anxiety and depressive symptoms are present and severe enough to justify individual diagnoses, both diagnoses should be recorded and this category should not be used."

<span class="mw-page-title-main">Social anxiety disorder</span> Anxiety disorder associated with social situations

Social anxiety disorder (SAD), also known as social phobia, is an anxiety disorder characterized by sentiments of fear and anxiety in social situations, causing considerable distress and impairing ability to function in at least some aspects of daily life. These fears can be triggered by perceived or actual scrutiny from others. Individuals with social anxiety disorder fear negative evaluations from other people.

<span class="mw-page-title-main">Selective serotonin reuptake inhibitor</span> Class of antidepressant medication

Selective serotonin reuptake inhibitors (SSRIs) are a class of drugs that are typically used as antidepressants in the treatment of major depressive disorder, anxiety disorders, and other psychological conditions.

Stefan G. Hofmann is a German-born clinical psychologist. He is the Alexander von Humboldt Professor and recipient of the LOEWE Spitzenprofessur for Translational Clinical Psychology at the Philipps University of Marburg in Germany, examining cognitive behavioral therapy, especially for anxiety disorders.

References

  1. 1 2 "International Forum on Mood and Anxiety Disorders | UIA Yearbook Profile | Union of International Associations". uia.org. Retrieved 2020-09-08.
  2. ↑ Papakostas, George I. (2009). "Switching Antidepressants vs. Conventional Augmentation Strategies". CNS Spectrums. 14 (S4): 11–14. doi:10.1017/S1092852900003527. ISSN   2165-6509. PMID   19407715. S2CID   23608072.
  3. ↑ "ABOUT US | IFMAD" . Retrieved 2020-09-08.
  4. ↑ "Previous meetings | IFMAD" . Retrieved 2020-09-08.
  5. ↑ "CONGRESSES & PUBLICATIONS – AFISM" . Retrieved 2020-09-08.
  6. ↑ "Scientific Program -". Archived from the original on December 5, 2024.
  7. ↑ "Ifmad 2025 – Budapest – June 2025" . Retrieved 2024-11-07.
  8. ↑ "The 20th International Forum on Mood and Anxiety Disorders". ConferenceLists.org. Retrieved 2024-11-07.
  9. ↑ "Scientific Program - Virtual" (PDF).[ permanent dead link ]
  10. ↑ "Scientific Programme – Ifmad 2021" . Retrieved 2021-03-21.
  11. ↑ "Ifmad 2021 – Budapest – July 2021" . Retrieved 2020-09-08.
  12. ↑ "The 18th International Forum on Mood and Anxiety Disorders" (PDF). IFMAD.
  13. ↑ "18th International Forum on Mood and Anxiety Disorders" (PDF).
  14. ↑ "IFMAD 2019" . Retrieved 2020-09-08.
  15. ↑ "EFPA Event: 18th International Forum on Mood and Anxiety Disorders - IFMAD". www.efpa.eu. Archived from the original on 2019-08-01. Retrieved 2020-09-08.
  16. ↑ "The 18th International Forum on Mood and Anxiety Disorders". www.conferencealerts.com. Retrieved 2020-09-08.
  17. ↑ "17th International Forum on Mood and Anxiety Disorders" (PDF). Ifmad.org. Retrieved 2018-03-07.
  18. ↑ "17th International Forum on Mood and Anxiety Disorders" (PDF). Ifmad.org. Retrieved 2018-03-07.
  19. ↑ "IFMAD 2017". ifmad.org.
  20. ↑ "17th International Forum on Mood and Anxiety Disorders (IFMAD 2017) | SPPSM". www.sppsm.org (in European Portuguese). Retrieved 2020-09-08.[ permanent dead link ]
  21. ↑ "17th International Forum on Mood and Anxiety Disorders (IFMAD 2017)". eanpages. Retrieved 2020-09-08.
  22. ↑ "16th International Forum on Mood and Anxiety Disorders" (PDF). Ifmad.org. Retrieved 2016-07-18.
  23. ↑ "16th International Forum on Mood and Anxiety Disorders" (PDF). Ifmad.org. Retrieved 2016-07-18.
  24. ↑ "IFMAD 2016". ifmad.org.
  25. ↑ "16th International Forum on Mood and Anxiety Disorders, IFMAD". www.science-community.org. Retrieved 2020-09-08.
  26. ↑ "15th International Forum on Mood and Anxiety Disorders" (PDF). Ifmad.org. Retrieved 2016-07-18.
  27. ↑ "15th International Forum on Mood and Anxiety Disorders" (PDF). Ifmad.org. Retrieved 2016-07-18.
  28. ↑ "IFMAD 2015". ifmad.org.
  29. ↑ "PSYCHIATRICKÁ SPOLEČNOST ČLS JEP ČESKÁ PSYCHIATRICKÁ SPOLEČNOST z.s." (PDF). 15th International Forum on Mood and Anxiety Disorders.
  30. ↑ "14th International Forum on Mood and Anxiety Disorders" (PDF). Ifmad.org. Retrieved 2016-07-18.
  31. ↑ "14th International Forum on Mood and Anxiety Disorders" (PDF). Ifmad.org. Retrieved 2016-07-18.
  32. ↑ "IFMAD 2014 - VIENNA, 10 – 12 DECEMBER, 2014". ifmad.org.
  33. ↑ "14th International Forum on Mood and Anxiety Disorders 2014 (IFMAD 2014)". AllCongress. Retrieved 2020-09-08.[ dead link ]
  34. ↑ "International Journal of Psychiatry in Clinical Practice" (PDF). Ifmad.org. Retrieved 2016-07-18.
  35. ↑ "13th International Forum on Mood and Anxiety Disorders" (PDF). Ifmad.org. Retrieved 2016-07-18.
  36. ↑ "IFMAD 2013 - Monaco 20 – 22 November 2013". ifmad.org.
  37. ↑ "VVP Agenda". vvponline.be. Retrieved 2020-09-08.
  38. ↑ "International Journal of Psychiatry in Clinical Practice" (PDF). Ifmad.org. Retrieved 2016-07-18.
  39. ↑ "12th International Forum on Mood and Anxiety Disorder" (PDF). Ifmad.org. Retrieved 2016-07-18.
  40. ↑ "IFMAD 2012". ifmad.org.
  41. ↑ "12th International Forum in Mood and Anxiety Disorders, IFMAD November 07 – 09, 2012, Barcelona, Spain | Paragon | Professional Congress Organizer | Event Management | PCO". Archived from the original on 2020-09-23. Retrieved 2020-09-08.
  42. ↑ "International Journal of Psychiatry in Clinical Practice" (PDF). Ifmad.org. Retrieved 2016-07-18.
  43. ↑ "11th International Forum on Mood and Anxiety Disorder" (PDF). Ifmad.org. Retrieved 2016-07-18.
  44. ↑ "Ifmad 2011 - 11th International Forum on Mood and Anxiety Disorders". ifmad.org.
  45. ↑ "The Impact of Financial Crisis on Depression and Anxiety: Evidence from a Depression Telephone Helpline". ResearchGate.
  46. ↑ "International Journal of Psychiatry in Clinical Practice" (PDF). Ifmad.org. Retrieved 2016-07-18.
  47. ↑ "10th International Forum on Mood and Anxiety Disorder" (PDF). Ifmad.org. Retrieved 2016-07-18.
  48. ↑ "mptpszichiatria" (PDF).
  49. ↑ "Volume 13, Number s01 (October 2009)". informahealthcare.com.
  50. ↑ "9th International Forum on Mood and Anxiety Disorder" (PDF). Ifmad.org. Retrieved 2016-07-18.
  51. ↑ Kasper, S. (2009). "9th International Forum on Mood and Anxiety Disorders". International Journal of Psychiatry in Clinical Practice. 13 (Suppl 1): 6–22. doi:10.3109/13651500903375487. PMID   24922315. S2CID   44548298.
  52. ↑ "International Journal of Psychiatry in Clinical Practice, 2008" (PDF). Ifmad.org. Retrieved 2016-07-18.
  53. ↑ "8th International Forum on Mood and Anxiety Disorder???" (PDF). Ifmad.org. Retrieved 2016-07-18.
  54. ↑ "8th International Forum on Mood and Anxiety Disorders". www.aimgroupinternational.com. Retrieved 2020-09-08.[ permanent dead link ]
  55. ↑ "International Journal of Psychiatry in Clinical Practice; 2007" (PDF). Ifmad.org. Retrieved 2016-07-18.
  56. ↑ "7th International Forum on Mood and Anxiety Disorder" (PDF). Ifmad.org. Retrieved 2016-07-18.
  57. ↑ Connolly, S. J.; Fatato, Penny; Nichols, A.; Paul, J.; Guico-Pabia, Christine (2007). "Abstracts from the 7th international forum on mood and anxiety disorders". International Journal of Psychiatry in Clinical Practice. 11 (4): 295–340. doi:10.1080/13651500701745584. PMID   24940731. S2CID   205790080.
  58. ↑ "Abstracts From The 6th International Forum on Mood and Anxiety Disorder" (PDF). Ifmad.org. Retrieved 2016-07-18.
  59. ↑ "6th International Forum on Mood and Anxiety Disorder" (PDF). Ifmad.org. Retrieved 2016-07-18.
  60. ↑ "Forthcoming international events" (PDF). Cambridge University.
  61. ↑ "International Journal of Psychiatry in Clinical Practice, 2005" (PDF). Ifmad.org. Retrieved 2016-07-18.
  62. ↑ "5th International Forum on Mood and Anxiety Disorder" (PDF). Ifmad.org. Retrieved 2016-07-18.
  63. ↑ "Predictors and prevention of suicide" (PDF). Publications Prof. Jules Angst.
  64. ↑ "Speaker Abstracts" (PDF). Ifmad.org. Retrieved 2016-07-18.
  65. ↑ "4th International Forum on Mood and Anxiety Disorder" (PDF). Ifmad.org. Retrieved 2016-07-18.
  66. ↑ "registration information". www.aimgroupinternational.com. Retrieved 2020-09-08.[ permanent dead link ]
  67. ↑ Gruettert, Torsten; Friege, Lars (2005-01-01). "Quetiapine in patients with borderline personality disorder and psychosis: a case series". International Journal of Psychiatry in Clinical Practice. 9 (3): 180–186. doi:10.1080/13651500510029048. ISSN   1365-1501. PMID   24937788. S2CID   9525235.
  68. ↑ "International Forum on Mood and Anxiety Disorders" (PDF). Ifmad.org. Retrieved 2016-07-18.
  69. ↑ Hemels, Michiel EH; Kasper, Siegfried; Walter, Evelyn; Einarson, Thomas R (2004-06-01). "Cost-Effectiveness of Escitalopram versus Citalopram in the Treatment of Severe Depression". Annals of Pharmacotherapy. 38 (6): 954–960. doi:10.1345/aph.1E010. ISSN   1060-0280. PMID   15113989. S2CID   5823767.
  70. ↑ "2nd International Forum on Mood and Anxiety Disorders (28.11.–1.12.2001, Monte Carlo) - Psychiatria ~ Psychoterapia ~ Psychosomatika". www.psychiatria-casopis.sk. Retrieved 2020-09-08.
  71. ↑ "New study suggests anti-epileptic medication, Topamax, can improve manic symptoms of bipolar disorder". EurekAlert!. Retrieved 2020-09-08.
  72. ↑ Kaschka, W. P.; Meyer, A.; Schier, K. R.; Fröscher, W. (2001). "Treatment of Pathological Crying with Citalopram". Pharmacopsychiatry (in German). 34 (6): 254–258. doi:10.1055/s-2001-18031. ISSN   0176-3679. PMID   11778147. S2CID   260241942.
  73. ↑ "Conference Calendar". Australasian Psychiatry. 8 (2): 188–191. 2000. doi:10.1046/j.1440-1665.2000.0256h.x. ISSN   1440-1665. S2CID   208501618.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.